Episode Details
Back to EpisodesHER2+ Genitourinary Cancers: Targeted Therapy Highlights From ESMO 2025
Episode 646
Published 2 months, 3 weeks ago
Description
Drs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.